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PREAMBLE
Organ transplantation, one of the medical miracles of the
twentieth century, has prolonged and improved the lives of
hundreds of thousands of patients worldwide. The many
great scientific and clinical advances of dedicated health
professionals, as well as countless acts of generosity by organ
donors and their families, have made transplantation not
only a life-saving therapy but also a shining symbol of human
solidarity. Yet, these accomplishments have been tarnished by
numerous reports of trafficking in human beings who are
used as sources of organs and of patient-tourists from rich
countries who travel abroad to purchase organs from poor
people. In 2004, the World Health Organization, called on
member states ‘to take measures to protect the poorest and
vulnerable groups from transplant tourism and the sale of
tissues and organs, including attention to the wider problem
of international trafficking in human tissues and organs.’1
To address the urgent and growing problems of organ
sales, transplant tourism, and trafficking in organ donors in
the context of the global shortage of organs, a Summit
Meeting of more than 150 representatives of scientific and
medical bodies from around the world, government officials,
social scientists, and ethicists, was held in Istanbul from 30
April to 2 May 2008. Preparatory work for the meeting was
undertaken by a Steering Committee convened by The
Transplantation Society (TTS) and the International Society
of Nephrology (ISN) in Dubai in December 2007. That
committee’s draft declaration was widely circulated and then
revised in light of the comments received. At the Summit, the
revised draft was reviewed by working groups and finalized in
plenary deliberations.
This Declaration represents the consensus of the Summit
participants. All countries need a legal and professional
framework to govern organ donation and transplantation
activities, as well as a transparent regulatory oversight system
that ensures donor and recipient safety and the enforcement
of standards and prohibitions on unethical practices.
Unethical practices are, in part, an undesirable consequence
of the global shortage of organs for transplantation. Thus, each
country should strive both to ensure that programs to prevent
organ failure are implemented and to provide organs to meet
the transplant needs of its residents from donors within its
own population or through regional cooperation. The
therapeutic potential of deceased organ donation should be
maximized not only for kidneys but also for other organs,
appropriate to the transplantation needs of each country.
Efforts to initiate or enhance deceased donor transplantation
are essential to minimize the burden on living donors.
Educational programs are useful in addressing the barriers,
misconceptions, and mistrust that currently impede the
development of sufficient deceased donor transplantation;
successful transplant programs also depend on the existence of
the relevant health system infrastructure.
Access to healthcare is a human right but often not a
reality. The provision of care for living donors before, during,
and after surgery—as described in the reports of the
international forums organized by TTS in Amsterdam and
Vancouver2–4—is no less essential than taking care of the
transplant recipient. A positive outcome for a recipient can
never justify harm to a live donor; on the contrary, for a
transplant with a live donor to be regarded as a success means
that both the recipient and the donor have done well.
This Declaration builds on the principles of the Universal
Declaration of Human Rights.5 The broad representation at
the Istanbul Summit reflects the importance of international
collaboration and global consensus to improve donation and
transplantation practices. The Declaration will be submitted
to relevant professional organizations and to the health
authorities of all countries for consideration. The legacy of
transplantation must not be the impoverished victims of
organ trafficking and transplant tourism but rather a
celebration of the gift of health by one individual to another.
DEFINITIONS
Organ trafficking is the recruitment, transport, transfer,
harboring, or receipt of living or deceased persons or their
organs by means of the threat or use of force or other forms of
coercion, of abduction, of fraud, of deception, of the abuse of
power or of a position of vulnerability, or of the giving to, or the
receiving by, a third party of payments, or benefits to achieve
the transfer of control over the potential donor for the purpose
of exploitation by the removal of organs for transplantation.6
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Transplant commercialism is a policy or practice in which
an organ is treated as a commodity, including by being
bought or sold or used for material gain.
Travel for transplantation is the movement of organs,
donors, recipients, or transplant professionals across jur-
isdictional borders for transplantation purposes. Travel for
transplantation becomes transplant tourism if it involves
organ trafficking and/or transplant commercialism or if the
resources (organs, professionals, and transplant centers)
devoted to providing transplants to patients from outside a
country undermine the country’s ability to provide trans-
plant services for its own population.
PRINCIPLES
(1) National governments, working in collaboration with
international and non-governmental organizations,
should develop and implement comprehensive programs
for the screening, prevention, and treatment of organ
failure, which include the following:
(a) The advancement of clinical and basic science
research.
(b) Effective programs, based on international guide-
lines, to treat and maintain patients with end-stage
diseases, such as dialysis programs for renal
patients, to minimize morbidity and mortality,
alongside transplant programs for such diseases.
(c) Organ transplantation as the preferred treatment
for organ failure for medically suitable recipients.
(2) Legislation should be developed and implemented by
each country or jurisdiction to govern the recovery of
organs from deceased and living donors and the practice of
transplantation, consistent with international standards.
(a) Policies and procedures should be developed and
implemented to maximize the number of organs
available for transplantation, consistent with these
principles.
(b) The practice of donation and transplantation
requires oversight and accountability by health
authorities in each country to ensure transparency
and safety.
(c) Oversight requires a national or regional registry to
record deceased and living donor transplants;
(d) Key components of effective programs include
public education and awareness, health professional
education and training, and defined responsibilities
and accountabilities for all stakeholders in the
national organ donation and transplant system.
(3) Organs for transplantation should be equitably allocated
within countries or jurisdictions to suitable recipients
without regard to gender, ethnicity, religion, or social or
financial status.
(a) Financial considerations or material gain of any
party must not influence the application of relevant
allocation rules.
(4) The primary objective of transplant policies and
programs should be optimal short- and long-term
medical care to promote the health of both donors and
recipients.
(a) Financial considerations or material gain of any
party must not override primary consideration for
the health and well-being of donors and recipients.
(5) Jurisdictions, countries, and regions should strive to
achieve self-sufficiency in organ donation by providing a
sufficient number of organs for residents in need from
within the country or through regional cooperation.
(a) Collaboration between countries is not inconsistent
with national self-sufficiency as long as the
collaboration protects the vulnerable, promotes
equality between donor and recipient populations,
and does not violate these principles.
(b) Treatment of patients from outside the country or
jurisdiction is only acceptable if it does not
undermine a country’s ability to provide transplant
services for its own population.
(6) Organ trafficking and transplant tourism violate the
principles of equity, justice, and respect for human
dignity and should be prohibited. Because transplant
commercialism targets impoverished and otherwise
vulnerable donors, it leads inexorably to inequity and
injustice and should be prohibited. In Resolution 44.25,
the World Health Assembly called on countries to
prevent the purchase and sale of human organs for
transplantation.
(a) Prohibitions on these practices should include a ban
on all types of advertising (including electronic and
print media), soliciting, or brokering for the
purpose of transplant commercialism, organ traf-
ficking, or transplant tourism.
(b) Such prohibitions should also include penalties for
acts—such as medically screening donors or organs,
or transplanting organs—that aid, encourage, or
use the products of organ trafficking or transplant
tourism.
(c) Practices that induce vulnerable individuals or
groups (such as illiterate and impoverished persons,
undocumented immigrants, prisoners, and political
or economic refugees) to become living donors are
incompatible with the aim of combating organ
trafficking, transplant tourism and transplant
commercialism.
PROPOSALS
Consistent with these principles, participants in the Istanbul
Summit suggest the following strategies to increase the donor
pool and to prevent organ trafficking, transplant commerci-
alism, and transplant tourism and to encourage legitimate,
life-saving transplantation programs:
To respond to the need to increase deceased donation:
(1) Governments, in collaboration with health-care institu-
tions, professionals, and non-governmental organizations,
should take appropriate actions to increase deceased organ
Kidney International (2008) 74, 854–859 855
The declaration of Istanbul p u b l i c f o r u m
donation. Measures should be taken to remove obstacles
and disincentives to deceased organ donation.
(2) In countries without established deceased organ dona-
tion or transplantation, national legislation should be
enacted that would initiate deceased organ donation and
create transplantation infrastructure, so as to fulfill each
country’s deceased donor potential.
(3) In all countries in which deceased organ donation has
been initiated, the therapeutic potential of deceased organ
donation and transplantation should be maximized.
(4) Countries with well-established deceased donor trans-
plant programs are encouraged to share information,
expertise, and technology with countries seeking to
improve their organ donation efforts.
To ensure the protection and safety of living donors and
appropriate recognition for their heroic act while combating
transplant tourism, organ trafficking and transplant com-
mercialism:
(1) The act of donation should be regarded as heroic and
honored as such by representatives of the government
and civil society organizations.
(2) The determination of the medical and psychosocial
suitability of the living donor should be guided by the
recommendations of the Amsterdam and Vancouver
Forums.2–4
(a) Mechanisms for informed consent should incorpo-
rate provisions for evaluating the donor’s under-
standing, including assessment of the psychological
impact of the process.
(b) All donors should undergo psychosocial
evaluation by mental health professionals during
screening.
(3) The care of organ donors, including those who have been
victims of organ trafficking, transplant commercialism,
and transplant tourism, is a critical responsibility of all
jurisdictions that sanctioned organ transplants utilizing
such practices.
(4) Systems and structures should ensure standardization,
transparency, and accountability of support for donation.
(a) Mechanisms for transparency of process and follow-
up should be established.
(b) Informed consent should be obtained both for
donation and for follow-up processes.
(5) Provision of care includes medical and psychosocial care
at the time of donation and for any short- and long-term
consequences related to organ donation.
(a) In jurisdictions and countries that lack universal
health insurance, the provision of disability, life,
and health insurance related to the donation event
is a necessary requirement in providing care for the
donor.
(b) In those jurisdictions that have universal health
insurance, governmental services should ensure
donors have access to appropriate medical care
related to the donation event.
(c) Health and/or life insurance coverage and employ-
ment opportunities of persons who donate organs
should not be compromised.
(d) All donors should be offered psychosocial services
as a standard component of follow-up.
(e) In the event of organ failure in the donor, the donor
should receive the following:
(i) Supportive medical care, including dialysis for
those with renal failure, and
(ii) Priority for access to transplantation, integrated
into existing allocation rules as they apply to
either living or deceased organ transplantation.
(6) Comprehensive reimbursement of the actual, documen-
ted costs of donating an organ does not constitute a
payment for an organ, but is rather part of the legitimate
costs of treating the recipient.
(a) Such cost reimbursement would usually be made by
the party responsible for the costs of treating the
transplant recipient (such as, a government health
department or a health insurer).
(b) Relevant costs and expenses should be calculated
and administered using transparent methodology,
consistent with national norms.
(c) Reimbursement of approved costs should be made
directly to the party supplying the service (such as,
to the hospital that provided the donor’s medical
care).
(d) Reimbursement of the donor’s lost income and out-
of-pocket expenses should be administered by the
agency handling the transplant rather than paid
directly from the recipient to the donor.
(7) Legitimate expenses that may be reimbursed when
documented include the following:
(a) The cost of any medical and psychological evalua-
tions of potential living donors who are excluded
from donation (e.g., because of medical or im-
munologic issues discovered during the evaluation
process).
(b) Costs incurred in arranging and effecting the pre-,
peri-, and postoperative phases of the donation
process (e.g., long-distance telephone calls, travel,
accommodation, and subsistence expenses).
(c) Medical expenses incurred for post-discharge care
of the donor.
(d) Lost income in relation to donation (consistent
with national norms).
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APPENDIX Process and Participant Selection
Steering Committee
The Steering Committee was selected by an Organizing
Committee consisting of Mona Alrukhami, Jeremy Chapman,
Francis Delmonico, Mohamed Sayegh, Faissal Shaheen, and
Annika Tibell.
The Steering Committee was composed of leadership from
The Transplantation Society, including its President-elect and
the Chair of its Ethics Committee, and the International
Society of Nephrology, including its Vice President and
individuals holding Council positions. The Steering Com-
mittee had representation from each of the continental
regions of the globe with transplantation programs.
The mission of the Steering Committee was to draft a
Declaration for consideration by a diverse group of
participants at the Istanbul Summit. The Steering Committee
also had the responsibility to develop the list of participants
to be invited to the Summit meeting.
Istanbul Participant Selection
Participants at the Istanbul Summit were selected by the
Steering Committee according to the following considerations:
K The country liaisons of The Transplantation Society
representing virtually all countries with transplantation
programs;
K Representatives from international societies and the
Vatican;
K Individuals holding leadership positions in nephrology
and transplantation;
K Stakeholders in the public policy aspect of organ
transplantation; and
K Ethicists, anthropologists, sociologists, and legal scholars
well recognized for their writings regarding transplanta-
tion policy and practice.
No person or group was polled with respect to their
opinion, practice, or philosophy prior to the Steering
Committee selection or the Istanbul Summit.
After the proposed group of participants was prepared and
reviewed by the Steering Committee, they were sent a letter of
invitation to the Istanbul Summit, which included the
following components:
K the mission of the Steering Committee to draft a
Declaration for all Istanbul participants’ consideration;
K the agenda and work group format of the Summit;
K the procedure for the selection of participants;
K the work group topics;
K an invitation to the participants to indicate their work
group preferences;
K the intent to communicate a draft and other materials
before the Summit convened;
K the Summit goals to assemble a final declaration that
could achieve consensus and would address the issues of
organ trafficking, transplant tourism and commercialism,
and provide principles of practice and recommended
alternatives to address the shortage of organs;
K an acknowledgment of the funding provided by Astellas
Pharmaceuticals for the Summit;
K provision of hotel accommodations and travel for all
invited participants.
Of approximately 170 persons invited, 160 agreed to
participate and 152 were able to attend the Summit in
Istanbul on 30 April to 2 May 2008. Because work on the
Declaration at the Summit was to be carried out by dividing
the draft document into separate parts, Summit invitees were
assigned to a work group topic based on their response
concerning the particular topics on which they wished to
focus their attention before and during the Summit.
Preparation of the Declaration
The draft Declaration prepared by the Steering Committee
was furnished to all participants with ample time for
appraisal and response prior to the Summit. The comments
and suggestions received in advance were reviewed by the
Steering Committee and given to leaders of the appropriate
work group at the Summit. (Work group leaders were
selected and assigned from the Steering Committee.)
The Summit meeting was formatted so that breakout
sessions of the work groups could consider the written
responses received from participants prior to the Summit as
well as comments from each of the work group participants.
The work groups elaborated these ideas as proposed
additions to and revisions of the draft. When the Summit
reconvened in plenary session, the Chairs of each work group
presented the outcome of their breakout session to all
Summit participants for discussion. During this process of
review, the wording of each section of the Declaration was
displayed on a screen before the plenary participants and was
modified in light of their comments until consensus was
reached on each point.
The content of the Declaration is derived from the
consensus that was reached by the participants at the Summit
in the plenary sessions which took place on 1 and 2 May
2008. A formatting group was assembled immediately
after the Summit to address punctuation, grammatical, and
related concerns and to record the Declaration in its finished
form.
Kidney International (2008) 74, 854–859 857
The declaration of Istanbul p u b l i c f o r u m
Participants in the Istanbul Summit
Last name First name Country
Abboud Omar Sudan
Abbud-Filhoa Mario Brazil
Abdramanov Kaldarbek Kyrgyzstan
Abdulla Sadiq Bahrain
Abraham Georgi India
Abueva Amihan V. Philippines
Aderibigbe Ademola Nigeria
Al-Mousawia Mustafa Kuwait
Alberu Josefina Mexico
Allen Richard D.M. Australia
Almazan-Gomez Lynn C. Philippines
Alnono Ibrahim Yemen
Alobaidlia Ali Abdulkareem United Arab Emirates
Alrukhaimia Mona United Arab Emirates
A´lvarez Ine´s Uruguay
Assad Lina Saudi Arabia
Assounga Alain G. South Africa
Baez Yenny Colombia
Bagheria Alireza Iran
Bakra Mohamed Adel Egypt
Bamgboye Ebun Nigeria
Barbaria Antoine Lebanon
Belghiti Jacques France
Ben Abdallah Taieb Tunisia
Ben Ammar Mohamed Salah Tunisia
Bos Michael The Netherlands
Britz Russell South Africa
Budiani Debra Untied States
Caprona Alexander Untied States
Castro Cristina R. Brazil
Chapmana Jeremy Australia
Chen Zhonghua Klaus People’s Republic of China
Codreanu Igor Moldova
Cole Edward Canada
Cozzi Emanuele Italy
Danovitcha Gabriel Untied States
Davids Razeen South Africa
De Broe Marc Belgium
De Castroa Leonardo Philippines
Delmonicoa Francis L. Untied States
Derani Rania Syria
Dittmer Ian New Zealand
Domı´nguez-Gil Beatriz Spain
Duro-Garcia Valter Brazil
Ehtuish Ehtuish Libya
El-Shoubaki Hatem Qatar
Epstein Miran United Kingdom
Fazela Iraj Iran
Fernandez Zincke Eduardo Belgium
Garcia-Gallont Rudolf Guatemala
Ghods Ahad J. Iran
Gill John Canada
Glotz Denis France
Gopalakrishnan Ganesh India
Gracida Carmen Mexico
Grinyo Josep Spain
Ha Jongwon South Korea
Haberala Mehmet A. Turkey
Hakim Nadey United Kingdom
Harmon William Untied States
Hasegawa Tomonori Japan
Hassan Ahmed Adel Egypt
Hickey David Ireland
Hiesse Christian France
Hongji Yang People’s Republic of China
Humar Ines Croatia
Hurtado Abdias Peru
Continued
Last name First name Country
Ismail Moustafa Wesam Egypt
Ivanovski Ninoslav Macedonia
Jhaa Vivekanand India
Kahn Delawir South Africa
Kamel Refaat Egypt
Kirpalani Ashok India
Kirste Guenter Germany
Kobayashia Eiji Japan
Koller Jan Slovakia
Kranenburg Leonieke The Netherlands
Lameirea Norbert Belgium
Laouabdia-Sellami Karim France
Lei Ruipeng People’s Republic of China
Levina Adeera Canada
Lloveras Josep Spain
Lo˜hmus Aleksander Estonia
Luciolli Esmeralda France
Lundin Susanne Sweden
Lye Wai Choong Singapore
Lynch Stephen Australia
Maı¨gaa Mahamane Mali
Mamzer Bruneel Marie-France France
Maric Nicole Austria
Martina Dominique Australia
Masria Marwan Lebanon
Matamoros Maria A. Costa Rica
Matas Arthur Untied States
McNeil Adrian United Kingdom
Meiser Bruno Germany
Mesˇi Enisa Bosnia
Moazam Farhat Pakistan
Mohsin Nabil Oman
Mor Eytan Israel
Morales Jorge Chile
Munn Stephen New Zealand
Murphy Mark Ireland
Naickera Saraladevi South Africa
Naqvi S.A. Anwar Pakistan
Noe¨la Luc World Health Organization
Obrador Gregorio Mexico
Oliveros Yolanda Philippines
Ona Enrique Philippines
Oosterlee Arie The Netherlands
Oyen Ole Norway
Padilla Benita Philippines
Pratschke Johann Germany
Rahamimov Ruth Israel
Rahmel Axel The Netherlands
Reznik Oleg Russia
Rizvia S. Adibul Hasan Pakistan
Roberts Lesley Ann Trinidad and Tobago
Rodriguez-Iturbea Bernardo Venezuela
Rowinski Wojciech Poland
Saeed Bassam Syria
Sarkissian Ashot Armenia
Sayegha Mohamed H. Untied States
Scheper-Hughes Nancy Untied States
Sever Mehmet Sukru Turkey
Shaheena Faissal A. Saudi Arabia
Sharma Dhananjaya India
Shinozaki Naoshi Japan
Simforoosh Nasser Iran
Singh Harjit Malaysia
Sok Hean Thong Cambodia
Somerville Margaret Canada
Stadtler Maria Untied States
Stephana Antoine Lebanon
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Last name First name Country
Sua´rez Juliette Cuba
Suaudeau Msgr. Jacques Italy
Sumethkul Vasant Thailand
Takahara Shiro Japan
Thiel Gilbert T. Switzerland
Tibella Annika Sweden
Tomadze Gia Georgia
Tonga Matthew Kwok-Lung Hong Kong
Tsai Daniel Fu-Chang Taiwan
Uriarte Remedios Philippines
Vanrenterghem Yves F.C. Belgium
Vathsalaa A. Singapore
Weimar Willem The Netherlands
Wikler Daniel Untied States
Young Kimberly Canada
Yuldashev Ulugbek Uzbekistan
Zhao Minggang People’s Republic of China
aMembers of the Steering Committee. (William Couser, USA, was also a member of
the Steering Committee but was unable to attend the Summit.)
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